Artal Group’s Ambrx Biopharma Inc AMAM Stock Holding History

Artal Group’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-702,291	Closed	-$11.6M	–	125
2023 Q2	$11.6M	Hold	702,291	–	–	0.36%	43
2023 Q1	$6.26M	Sell	702,291 -1,450,000	-67%	-$7.29M	0.37%	56
2022 Q4	$4.89M	Hold	2,152,291	–	–	0.27%	64
2022 Q3	$2.32M	Hold	2,152,291	–	–	0.1%	86
2022 Q2	$5.7M	Hold	2,152,291	–	–	0.3%	52
2022 Q1	$8.87M	Hold	2,152,291	–	–	0.37%	53
2021 Q4	$19.4M	Buy	2,152,291 +1,302,291	+153%	+$14.5M	0.53%	48
2021 Q3	$11.5M	Hold	850,000	–	–	0.26%	73
2021 Q2	$16.7M	Buy	+850,000	New	+$14.5M	0.34%	64

Other funds holding AMAM

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Artal Group's AMAM Position: Q3 2023 in Review

Artal Group sold out of Ambrx Biopharma Inc (AMAM) in Q3 2023, closing a stake of 702,291 shares — an estimated $11.6M sold.

Artal Group first reported a position in AMAM in Q2 2021 and held it in 9 quarters. The position peaked at $19.4M in Q4 2021. 44 funds tracked by Wall St. Rank hold AMAM as of Q3 2023.

Artal Group reported no remaining Ambrx Biopharma Inc position as of Q3 2023 after selling out during the quarter.
Artal Group sold 702,291 Ambrx Biopharma Inc shares in Q3 2023, an estimated $11.6M.
Artal Group first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 9 quarters.
Artal Group's Ambrx Biopharma Inc position peaked at $19.4M in Q4 2021.
44 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.